Selective inhibition of factor Xa is more efficient than factor VIIa-tissue factor complex blockade at facilitating coronary thrombolysis in the canine model

Journal of the American College of Cardiology

Volumn 28, Issue 7, 1997, Pages 1858-1865

  Lefkovits, Jeffrey ^a   Malycky, Janis L ^b   Rao, J Sunil ^a   Hart, Charles E ^a   Plow, Edward F ^b   Topol, Eric J ^b   Nicolini, Francesca A ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b ZYMOGENETICS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE; BLOOD CLOTTING FACTOR 7A; BLOOD CLOTTING INHIBITOR; RECOMBINANT TISSUE FACTOR PATHWAY INHIBITOR; TICK ANTICOAGULANT PEPTIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD CLOT LYSIS; CONTROLLED STUDY; CORONARY ARTERY THROMBOSIS; DOG; DRUG EFFICACY; FEMALE; INTRAARTERIAL DRUG ADMINISTRATION; MALE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; BLOOD COAGULATION; CORONARY THROMBOSIS; DOGS; FACTOR VIIA; FACTOR XA; HEMOSTASIS; LIPOPROTEINS; PEPTIDES; THROMBOLYTIC THERAPY; THROMBOPLASTIN; TISSUE PLASMINOGEN ACTIVATOR;

EID: 0030466724     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(96)00401-9     Document Type: Article

References (42)

1. Lincoff AM, Topol EJ. Illusion of reperfusion: does anyone achieve optimal reperfusion during acute myocardial infarction? Circulation 1993;87:1792-1805.
2. Sitko GR, Ramjit DR, Stabilito II, Lehman D, Lynch JJ Jr, Vlasuk GP. Conjunctive enhancement of enzymatic thrombolysis and prevention of thrombotic reocclusion with selective factor Xa inhibitor, tick anticoagulant peptide. Comparison to hirudin and heparin in a canine model of acute artery thrombosis. Circulation 1992;85:805-15.
3. Lynch JJ Jr, Sitko GR, Mellott MJ, et al. Maintenance of canine coronary artery patency following thrombolysis with front loaded plus low dose maintenance conjunctive therapy. A comparison of factor Xa versus thrombin inhibition. Cardiovasc Res 1994;28:78-85.
4. Nicolini FA, Lee P, Malycky JL, et al. Selective inhibition of factor Xa during thrombolytic therapy markedly improves coronary artery patency in a canine model of coronary thrombosis. Blood Coagul Fibrinolysis 1996;7:39-48.
5. Davie EW, Fujikawa K, Kisiel W. The coagulation cascade: initiation, maintenance and regulation. Biochemistry 1991;30:10363-70.
6. ten Cate H, Bauer KA, Levi M, et al. The activation of factor X and prothrombin by recombinant factor VIIa in vivo is mediated by tissue factor. J Clin Invest 1993;92:1207-12.
7. Vlasuk GP. Structural and functional characterization of tick anticoagulant peptide (TAP): a potent and selective inhibitor of blood coagulation factor Xa. Thromb Haemost 1993;70:212-6.
8. Broze GJ, Girard TJ, Novotny WF. Regulation of coagulation by a multivalent Kunitz-type inhibitor. Biochemistry 1990;29:7539-46.
9. Rapaport SI. The extrinsic pathway inhibitor: a regulator of tissue-factor dependent blood coagulation. Thromb Haemost 1991;66:6-15.
10. Nicolini FA, Mehta JL, Nichols WW, Saldeen TG, Grant M. Prostacyclin analogue iloprost decreases thrombolytic potential of tissue-type plasminogen activator in canine coronary thrombosis. Circulation 1990;81:1115-22.
11. Nicolini FA, Nichols WW, Saldeen TG, Mehta JL. Pathological basis of failure of concurrent glyceryl trinitrate therapy to improve efficacy of tissue type plasminogen activator in coronary thrombosis. Cardiovasc Res 1991;25:283-9.
12. Romson JL, Haack DW, Lucchesi BR. Electrical induction of coronary artery thrombosis in the ambulatory canine, a model for in vivo evaluation of antithrombotic agents. Thromb Res 1980;17:841-53.
13. Jang Y, Guzman LA, Lincoff AM, et al. The influence of blockade at specific levels of the coagulation cascade on restenosis in a rabbit atherosclerotic femoral artery injury model. Circulation 1995;92:3041-50.
14. Lindahl AK, Wildgoose P, Lumsden AB, et al. Active site-inhibited factor VIIa blocks tissue factor activity and prevents arterial thrombus formation in baboons [abstract]. Circulation 1993;88 Suppl 1:1-417.
15. Haskel EJ, Torr SR, Day KC, et al. Prevention of arterial reocclusion after thrombolysis with recombinant lipoprotein-associated coagulation inhibitor. Circulation 1991;84:821-7.
16. Abendschein DR, Meng YY, Torr-Brown S, Sobel BE. Maintenance of coronary patency after fibrinolysis with tissue factor pathway inhibitor. Circulation 1995;92:944-9.
17. Diaz-Collier JA, Palmier MO, Kretzmer KK, et al. Refold and characterization of recombinant tissue factor pathway inhibitor expressed in Escherichia coli. Thromb Haemost 1994;71:339-46.
18. Vlasuk GP, Ramjit D, Fujita T, et al. Comparison of the in vivo anticoagulant properties of standard heparin and the highly selective factor Xa inhibitors antistasin and tick anticoagulant peptide (TAP) in a rabbit model of venous thrombosis. Thromb Haemost 1991;65:257-62.
19. Nicolini FA, Lee P, Rios G, Kottke-Marchant K, Topol EJ. Combination of platelet fibrinogen receptor antagonist and direct thrombin inhibitor at low doses markedly improves thrombolysis. Circulation 1994;89:1802-9.
20. Novotny WF, Brown SG, Miletich JP, Rader DJ, Broze GJ. Plasma antigen levels of the lipoprotein-associated coagulation inhibitor in patient samples. Blood 1991;78:387-93.
21. Jolley ME, Wang CH, Ekenberg SJ, Zuelke MS, Kelso DM. Particle concentration fluorescence immunoassay (PCFIA): a new, rapid immunoassay technique with high sensitivity. J Immunol Methods 1984;67:689-93.
22. Eisenberg PR, Siegel JE, Abendschein DR, Miletich JP. Importance of factor Xa in determining the procoagulant activity of whole-blood clots. J Clin Invest 1993;91:1877-83.
23. Prager NA, Abendschein DR, McKenzie CR, Eisenberg PR. Role of thrombin compared with factor Xa in the procoagulant activity of whole blood clots. Circulation 1995;92:962-7.
24. Neuenschwander P, Jesty J. A comparison of phospholipids and platelets in the activation of human factor VIII by thrombin and factor Xa, and the inactivation of factor Xa. Blood 1988;72:1761-70.
25. Warn-Cramer BJ, Rapaport SI. Evidence suggestive of activation of the intrinsic pathway of blood coagulation after injection of factor Xa/phospholipid into rabbits. Arterioscl Thromb Vasc Biol 1995;15:133-9.
26. Eisenberg PR, Sherman L, Rich M, et al. Importance of continued activation of thrombin reflected by fibrinopeptide A to the efficacy of thrombolysis. J Am Coll Cardiol 1986;7:1255-62.
27. Eisenberg PR, Miletich JP, Sobel BE. Factors responsible for the differential procoagulant effects of diverse plasminogen activators in plasma. Fibrinolysis 1991;5:217-24.
28. Ewald GA, Eisenberg PR. Plasmin-mediated activation of contact system in response to pharmacological thrombolysis. Circulation 1995;91:28-36.
29. Lee CD, Mann KG. The activation of human coagulation factor V by plasmin. Blood 1989;73:185-90.
30. Nicolini FA, Lee P, Rios G, Zajkowski Brown J, Plow EF. Selective inhibition of factor Xa and the prothrombinase complex prevents coronary rethrombosis [abstract]. Circulation 1994;90 Suppl 1:1-334.
31. Folts JD, Gallagher K, Rowe GG. Blood flow reductions in stenosed canine coronary arteries: vasospasm or platelet aggregation? Circulation 1982;65:248-54.
32. Schaffer LW, Davidson JT, Vlasuk GP, Siegl PKS. Antithrombotic efficacy of recombinant tick anticoagulant peptide, a potent inhibitor of coagulation factor Xa in a primate model of arterial thrombosis. Circulation 1991;84:1741-8.
33. Mellott MJ, Holahan MA, Lynch JJ Jr, Hasuk GP, Dunwiddie CT. Acceleration of recombinant tissue-type plasminogen activator-induced reperfusion and prevention of reocclusion by recombinant antistasin, a selective factor Xa inhibitor in a canine model of femoral arterial thrombosis. Circ Res 1992;70:1152-60.
34. Benedict C, Ryan J, Todd J, et al. Active site-blockade factor Xa prevents thrombus formation in the coronary vasculature parallel with inhibition of extravascular coagulation in a canine thrombosis model. Blood 1993;81:2059-66.
35. Mellott MJ, Stranieri MT, Sitlo GR, Stabilito II, Lynch JJ Jr, Vlasuk GP. Enhancement of recombinant tissue plasminogen activator-induced reperfusion by recombinant tick anticoagulant peptide, a selective factor Xa inhibitor, in a canine model of femoral arterial thrombosis. Fibrinolysis 1993;7:195-202.
36. Mruk JS, Zoldhelyi P, Webster MW, et al. Does antithrombotic therapy influence residual thrombus after thrombolysis of platelet-rich thrombus? Effects of recombinant hirudin, heparin, or aspirin. Circulation 1996;93:792-9.
37. Haskel EJ, Prager NA, Sobel BE, Abendschein DR. Relative efficacy of antithrombin compared with antiplatelet agents in accelerating coronary thrombolysis and preventing early reocclusion. Circulation 1991;83:1048-56.
38. Neuhaus KL, von Essen R, Tebbe U, et al. Safety observations from the pilot phase of the randomized r-hirudin for improvement of thrombolysis (HIT-III) study. A study of the Arbeitsgemeinschaft Leitender Kardiologischer Krankenhausarzte (ALKK). Circulation 1994;90:1638-42.
39. Cannon CP, McCabe CH, Henry TD, et al. A pilot trial of recombinant desulfatohirudin compared to heparin in conjunction with tissue plasminogen activator and aspirin for acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI) 5 trial. J Am Coll Cardiol 1994;23:993-1003.
40. Pawasche A, Golino P, Ambrosio G, et al. A monoclonal antibody against rabbit tissue factor inhibits thrombus formation in stenotic injured rabbit carotid arteries. Circ Res 1994;74:56-63.
41. Jang I, Gold H, Leinbach R, Fallon J, Collen D, Wilcox J. Antithrombotic effect of a monoclonal antibody against tissue factor in a rabbit model of platelet mediated arterial thrombosis. Arterioscler Thromb 1992;12:948-54.
42. Ragni M, Cirillo P, Pascucci I, et al. Monoclonal antibody against tissue factor shortens tissue plasminogen activator lysis time and prevents reocclusion in a rabbit model of carotid artery thrombosis. Circulation 1996;93:1913-8.